Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
Chiesi Farmaceutici and its subsidiary Skyline Merger Sub have outlined a proposed cash tender offer to acquire KalVista Pharmaceuticals for $27.00 per share under an Agreement and Plan of Merger dated April 28, 2026. The communication is a preliminary solicitation and states the Offer has not yet commenced.
The filing says Offer materials (a Schedule TO by Parent and Purchaser and a Schedule 14D-9 by KalVista) will be filed with the SEC when the Offer is launched; investors are directed to review those materials and the companies' SEC filings for details.
KalVista Pharmaceuticals, Inc. Schedule 13G/A amendment discloses passive, shared voting and dispositive power over 1,546,105 shares (3.0%) by Integrated Core Strategies (US) LLC and 1,912,146 shares (3.7%) by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing is a joint filing under a Joint Filing Agreement dated April 30, 2026.
The filing lists shared voting and disposition powers and clarifies the securities are held by entities subject to Millennium-related voting or investment discretion; signatures are provided by Gil Raviv and Israel A. Englander.
KalVista Pharmaceuticals, Inc. filed Amendment No. 1 to its transition Form 10-KT to add the disclosures required by Part II and Part III and to furnish new Section 302 certifications. The Amendment also discloses that on April 29, 2026 the company and certain subsidiaries entered into an Agreement and Plan of Merger providing for the acquisition of KalVista by Chiesi Farmaceutici S.p.A. through a merger in which KalVista will become a wholly owned subsidiary of Chiesi.
The Amendment restates that its Original Filing continues to speak as of the Original Filing date and that no other updates were made. It includes board and executive officer biographies, executive compensation disclosures for the 2025 transition period, equity plan and outstanding award tables, related-party transactions (including participation by certain holders in the November 2024 offering), and auditor fee disclosures.
KalVista Pharmaceuticals agreed to be acquired by Chiesi Group in an all-cash transaction. Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share, implying a total deal value of about $1.9 billion.
The offer is conditioned on a majority of shares being tendered, antitrust and foreign investment clearances, and customary accuracy, covenant and no–material-adverse-effect conditions. After the tender offer, a back-end merger under Section 251(h) of Delaware law will make KalVista a wholly owned Chiesi subsidiary.
KalVista’s board unanimously approved the merger agreement and recommends stockholders tender their shares. The agreement includes typical non-solicitation and fiduciary out provisions and a $66.4 million termination fee payable to Chiesi in specified circumstances. The parties expect closing in Q3 2026, subject to conditions.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity compensation activity and a related tax sale. On April 16, 6,250 restricted stock units vested into the same number of common shares at no cost, as part of a scheduled RSU vesting plan. A total of 2,686 common shares were then sold at an average price of $20.2163 solely to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. After these transactions, he directly holds 142,547 shares of common stock and 93,750 unvested RSUs that continue to vest quarterly, subject to continued service.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity and a related tax sale. On April 16, 2026, 6,250 restricted stock units converted into an equal number of common shares at no cost, reflecting RSU vesting. On April 17, 2026, 1,862 common shares were sold at $20.2163 per share solely to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. After these transactions, Sweeny directly held 51,391 shares of KalVista common stock. The RSU award vests in 16 equal quarterly installments starting on April 16, 2026, subject to continued service.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity. On April 16, 2026, 6,250 restricted stock units (RSUs) converted into the same number of common shares for no cash consideration, reflecting scheduled vesting. On April 17, 2026, he sold 1,862 common shares at $20.2163 per share in an open-market transaction specifically to cover tax withholding obligations from the RSU vesting, described as a nondiscretionary “sell to cover” sale. After these transactions, he directly held 18,150 common shares, and 93,750 RSUs remained outstanding, which continue to vest quarterly in 1/16 increments starting April 16, 2026, subject to continued service.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On April 16, 2026, restricted stock units vested and were settled into 20,312 shares of Common Stock at $0.00 per share, reflecting a compensation-related share delivery. To cover tax withholding obligations from this RSU vesting, he then sold 9,550 shares of Common Stock at an average price of $20.2163 per share on April 17, 2026 in a "sell to cover" transaction described as non-discretionary. Following these transactions, he holds 462,577 Common Stock shares directly.
KalVista Pharmaceuticals’ major shareholder funds reported open-market sales of 214,631 shares of Common Stock. The transactions were executed on March 25–26 at prices between approximately $16.95 and $19.12 per share through entities affiliated with Venrock Healthcare Capital Partners.
After these sales, the affiliated funds continue to hold about 5,089,354 shares indirectly. The filing clarifies that management entities and individuals associated with these funds may be deemed to beneficially own these securities only to the extent of any indirect pecuniary interest.
KalVista Pharmaceuticals filed a Transition Report on Form 10-KT for the eight-month fiscal transition period May 1, 2025 through December 31, 2025, noting a change in fiscal year end to December 31. The company launched EKTERLY® (sebetralstat) after FDA approval on July 3, 2025 and lists additional approvals in the E.U., U.K., Switzerland, Japan, Australia and Singapore. KalVista states it began U.S. and German commercial operations, has established regional partnerships and entered a royalty financing arrangement providing an upfront $100.0 million plus a $22.0 million one-time payment. Cash and cash equivalents were $229.3 million as of December 31, 2025, and shares outstanding were 51,222,487 as of March 18, 2026.